180 Participants Needed

uEXPLORER vs Conventional PET/CT Imaging for Cancer

Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: University of California, Davis
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

Trial Summary

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.

What data supports the effectiveness of the treatment mCT/uEXPLORER, uEXPLORER/mCT in the clinical trial titled 'uEXPLORER vs Conventional PET/CT Imaging for Cancer'?

Research shows that combining PET with CT in imaging provides better anatomical details and faster imaging, which is particularly useful in cancer care for staging tumors and monitoring therapy. This combined imaging approach has been shown to improve survival in certain cancers, like breast cancer and lung cancer, by helping doctors make more informed treatment decisions.12345

Is uEXPLORER PET/CT imaging safe for humans?

The uEXPLORER PET/CT scanner has been used in clinical settings and provides high-quality imaging with lower radiation doses, which suggests it is generally safe for human use. It offers better image quality and lower noise compared to conventional PET/CT, which can improve the accuracy of medical assessments.678910

How does the uEXPLORER PET/CT treatment differ from conventional PET/CT imaging for cancer?

The uEXPLORER PET/CT treatment is unique because it offers total-body imaging, which provides more comprehensive information about the disease compared to conventional PET/CT. It allows for low-dose or even extra low-dose scanning, reducing radiation exposure while maintaining high-quality imaging, and can dynamically assess tumor characteristics.3681112

What is the purpose of this trial?

To determine the minimum scan duration for fluorine-18 positron-emitting radioactive isotope-fluorodeoxyglucose (18F-FDG) positron emission tomography (PET)/computed tomography (CT) scans performed on a total-body PET/CT scanner that results in non-inferior image quality to 18F-FDG PET/CT scans performed on a conventional PET/CT scanner. The subject population will be patients being staged for lung cancer, lymphoma, or melanoma.

Research Team

LN

Lorenzo Nardo, MD

Principal Investigator

UC Davis Department of Radiology

Eligibility Criteria

This trial is for men and women over 18 who can consent to participate, have or might have lung cancer, lymphoma, or melanoma, and need a PET/CT scan. It's not for pregnant individuals, those with claustrophobia, or anyone with a condition that could affect their safety in the study.

Inclusion Criteria

I have been referred for a PET/CT scan.
Ability to understand and willingness to sign an informed consent form.
Ability to adhere to the study visit schedule and all protocol requirements.
See 1 more

Exclusion Criteria

Pregnant women.
You are afraid of being in small or enclosed spaces.
Any significant medical condition that in the opinion of the investigator would prevent the subject from participating and/or adhering to study related procedures or interfere with subject safety.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Imaging

Participants undergo PET/CT scans on both uEXPLORER and conventional PET/CT scanners to compare image quality and tumor recognition

1 day
1 imaging visit (in-person)

Follow-up

Participants are monitored for any adverse effects following the imaging procedures

4 weeks

Treatment Details

Interventions

  • mCT/uEXPLORER
  • uEXPLORER/mCT
Trial Overview The trial is testing if shorter scans using a new total-body PET/CT scanner (uEXPLORER) are as good as longer ones on conventional scanners for patients with lung cancer, lymphoma, or melanoma. Participants will undergo both types of scans.
Participant Groups
2Treatment groups
Experimental Treatment
Group I: uEXPLORER/mCTExperimental Treatment1 Intervention
Each patient will undergo a scan on a total-body PET/CT scanner (uEXPLORER) and then undergo an additional scan on a conventional PET/CT scanner (mCT). The first scan will take place 60 minutes after injection with 18F-FDG and the second scan will be 90 minutes after injection with 18F-FDG.
Group II: mCT/uEXPLORERExperimental Treatment1 Intervention
Each patient will undergo a scan on a conventional PET/CT scanner (mCT) and then undergo an additional scan on a total-body PET/CT scanner (uEXPLORER) . The first scan will take place 60 minutes after injection with 18F-FDG and the second scan will be 90 minutes after injection with 18F-FDG.

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of California, Davis

Lead Sponsor

Trials
958
Recruited
4,816,000+

Findings from Research

Imaging plays a crucial role in improving survival outcomes in cancer care, as evidenced by its effectiveness in various scenarios such as breast cancer screening and staging of non-small cell lung cancer.
Modeling studies suggest that the most significant survival benefits from imaging may be found in mildly symptomatic patients, while even modest improvements in survival can lead to reduced healthcare costs.
Can imaging help improve the survival of cancer patients?Miles, K.[2021]

References

Can imaging help improve the survival of cancer patients? [2021]
Added Value of Integrated Whole-Body PET/MRI for Evaluation of Colorectal Cancer: Comparison With Contrast-Enhanced MDCT. [2015]
Integrated modality imaging with PET-CT and SPECT-CT: CT issues. [2020]
Response monitoring in metastatic breast cancer: a comparison of survival times between FDG-PET/CT and CE-CT. [2023]
Significant benefit of multimodal imaging: PET/CT compared with PET alone in staging and follow-up of patients with Ewing tumors. [2016]
Optimal clinical protocols for total-body 18F-FDG PET/CT examination under different activity administration plans. [2023]
Radioembolization Dosimetry with Total-Body 90Y PET. [2023]
Total-Body PET/Computed Tomography Highlights in Clinical Practice: Experiences from Zhongshan Hospital, Fudan University. [2021]
A Prospective Study Assessing the Post-Prostatectomy Detection Rate of a Presumed Local Failure at mpMR with Either 64CuCl2 or 64CuPSMA PET/CT. [2021]
Multidetector CT in children: current concepts and dose reduction strategies. [2022]
11.United Statespubmed.ncbi.nlm.nih.gov
Summary of the UPICT Protocol for 18F-FDG PET/CT Imaging in Oncology Clinical Trials. [2018]
Whole-body imaging of oncologic patients using 16-channel PET-CT. Evaluation of an i.v. contrast enhanced MDCT protocol. [2016]
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of Service·Privacy Policy·Cookies·Security